Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220408 · ClinicalTrials.gov registry record · Phase 2
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by Telios Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07220408: Recruiting Phase 2 study of Allergic Conjunctivitis, sponsored by Telios Pharma.
NCT07220408 is a Phase 2 study of Allergic Conjunctivitis that is actively recruiting participants, run by Telios Pharma. The registered enrollment target is 60 participants, below the 132-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220408, a Phase 2 study of Allergic Conjunctivitis, is actively recruiting participants, sponsored by Telios Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Primary Outcome
Ocular itching score will be reported by the subject at 3 timepoints after CAC at Visits 4d , 5d, and 6c.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TL-925
Study Locations (1)
Tennessee
- Advancing Vision Research - Smyrna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
What NCT07220408 shows while recruiting
NCT07220408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 132-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220408 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07220408 about?
NCT07220408 is a clinical study titled "Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis". In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using th...
What is the current status of trial NCT07220408?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-10-23. Estimated completion is 2026-02.
What conditions does trial NCT07220408 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT07220408?
The interventions under investigation include: Placebo (DRUG), TL-925 (DRUG).
Who is sponsoring clinical trial NCT07220408?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220408 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220408's enrollment target sits among peer trials
60 15th of 20 higher than 6 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI